

Docket No.: 12475/51002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Robert E. Klem

SERIAL NO.

10/053,645

FILED

22 January 2002

FOR

Methods and Compositions for Treating a Cell-Proliferative Disorder Using CRE Decoy Oligomers, Bcl-2 Antisense Oligomers, and Hybrid

Oligomers Thereof

EXAMINER

Sean McGarry

GROUP ART UNIT

1635

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box SEQUENCE, P.O. Box 1450,

Alexandria, VA 22313-21450 on

COMMISSIONER FOR PATENTS

Box SEQUENCE

Alexandria, VA 22313-21450

Date: July 9,2004

Reg. No. 32,135

TRANSMITTAL

SIR:

Filed herewith is a Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed 10 June 2004. A response is due by 10 July 2004, and Applicant believes this Response is timely filed and that no fees are due in connection with this response. However, if any fees are due the Commissioner is hereby authorized to charge the necessary fees to Deposit Account No. 503154. A duplicate of this sheet is enclosed.

Respectfully submitted,

Donna R. Fugit, Ph.D

Reg. No. 32,135 Agent for Applicant

Genta, Inc. Two Connell Drive Berkeley Heights, NJ 07922 Tel. (908) 219-3195 Fax (908) 286-5982

Date: July 9, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Robert E. Klem

SERIAL NO.

10/053,645

FILED

22 January 2002

FOR

Methods and Compositions for Treating a Cell-Proliferative

Disorder Using CRE Decoy Oligomers, Bcl-2 Antisense

Oligomers, and Hybrid Oligomers Thereof

EXAMINER

Sean McGarry

GROUP ART UNIT:

1635

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box SEQUENCE, P.O. Box 1450, Alexandria, VA 22313-21450 on

COMMISSIONER FOR PATENTS

Box SEQUENCE

Alexandria, VA 22313-21450

Date: July 9,2004

Donna R. Fugit, Ph.D. Reg. No. 32,135

RESPONSE and STATEMENT UNDER 37 CFR §1.825(a) and 37 CFR §1.825(b)

SIR:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed 10 June 2004. A response is due by 10 July 2004. The Examiner's attention is drawn to the Power of Attorney (Revocation of Prior Powers) with change of correspondence address filed 9 March 2004 in the present application. A copy is enclosed as Exhibit A. It is respectfully requested that all future correspondence be mailed to Kenyon & Kenyon, Applicant's new representative.

Enclosed with this Response are 15 pages of substitute Sequence Listing in paper form (Exhibit B) and a Computer Readable Form containing a file corresponding to the paper

16 35

Docket No.: 12475/51002

ARK OFFICE

Serial No. 10/053,645

Attorney Docket No. 12475/51002

substitute Sequence Listing. Applicant hereby states that the enclosed paper copy of the substitute Sequence Listing contains no new matter, and that the Sequence Listing contained on the Computer Readable Form is the same as the paper copy of the substitute Sequence Listing.

Amendments to the Specification begin on page 3 of this Response.

Amendments to the Claims begin on page 12 of this Response.

Remarks begin on page 20 of this Response.

2